Internet Content & Information
Compare Stocks
4 / 10Stock Comparison
BODI vs NUS vs HIMS vs AMZN
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Medical - Equipment & Services
Specialty Retail
BODI vs NUS vs HIMS vs AMZN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Internet Content & Information | Household & Personal Products | Medical - Equipment & Services | Specialty Retail |
| Market Cap | $38M | $345M | $6.63B | $2.92T |
| Revenue (TTM) | $252M | $1.49B | $2.35B | $742.78B |
| Net Income (TTM) | $-3M | $160M | $128M | $90.80B |
| Gross Margin | 73.0% | 69.4% | 69.7% | 50.6% |
| Operating Margin | 3.2% | 4.4% | 4.6% | 11.5% |
| Forward P/E | — | 7.2x | 58.3x | 31.4x |
| Total Debt | $3M | $364M | $1.12B | $152.99B |
| Cash & Equiv. | $39M | $239M | $229M | $86.81B |
BODI vs NUS vs HIMS vs AMZN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| The Beachbody Compa… (BODI) | 100 | 2.6 | -97.4% |
| Nu Skin Enterprises… (NUS) | 100 | 12.4 | -87.6% |
| Hims & Hers Health,… (HIMS) | 100 | 148.9 | +48.9% |
| Amazon.com, Inc. (AMZN) | 100 | 170.1 | +70.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BODI vs NUS vs HIMS vs AMZN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BODI has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.37
- Lower volatility, beta 1.37, Low D/E 9.1%, current ratio 0.74x
- Beta 1.37 vs HIMS's 2.40, lower leverage
- +186.6% vs HIMS's -51.0%
NUS is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 1.49, yield 3.4%, current ratio 2.08x
- Lower P/E (7.2x vs 31.4x)
- 3.4% yield; the other 3 pay no meaningful dividend
HIMS is the clearest fit if your priority is growth exposure.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs BODI's -39.9%
AMZN is the clearest fit if your priority is long-term compounding.
- 7.0% 10Y total return vs HIMS's 161.9%
- 12.2% margin vs BODI's -1.1%
- 11.5% ROA vs BODI's -1.9%, ROIC 14.7% vs 46.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs BODI's -39.9% | |
| Value | Lower P/E (7.2x vs 31.4x) | |
| Quality / Margins | 12.2% margin vs BODI's -1.1% | |
| Stability / Safety | Beta 1.37 vs HIMS's 2.40, lower leverage | |
| Dividends | 3.4% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +186.6% vs HIMS's -51.0% | |
| Efficiency (ROA) | 11.5% ROA vs BODI's -1.9%, ROIC 14.7% vs 46.7% |
BODI vs NUS vs HIMS vs AMZN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BODI vs NUS vs HIMS vs AMZN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BODI leads in 2 of 6 categories
AMZN leads 1 • NUS leads 0 • HIMS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BODI and AMZN each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMZN is the larger business by revenue, generating $742.8B annually — 2950.7x BODI's $252M. AMZN is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to BODI's -1.1%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $252M | $1.5B | $2.3B | $742.8B |
| EBITDAEarnings before interest/tax | $26M | $118M | $164M | $155.9B |
| Net IncomeAfter-tax profit | -$3M | $160M | $128M | $90.8B |
| Free Cash FlowCash after capex | $17M | $46M | $73M | -$2.5B |
| Gross MarginGross profit ÷ Revenue | +73.0% | +69.4% | +69.7% | +50.6% |
| Operating MarginEBIT ÷ Revenue | +3.2% | +4.4% | +4.6% | +11.5% |
| Net MarginNet income ÷ Revenue | -1.1% | +10.8% | +5.5% | +12.2% |
| FCF MarginFCF ÷ Revenue | +6.9% | +3.1% | +3.1% | -0.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -35.7% | -16.9% | +28.4% | +16.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +115.1% | +139.7% | -27.3% | +74.8% |
Valuation Metrics
BODI leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 2.2x trailing earnings, NUS trades at a 96% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, BODI's 0.1x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $38M | $345M | $6.6B | $2.92T |
| Enterprise ValueMkt cap + debt − cash | $2M | $471M | $7.5B | $2.98T |
| Trailing P/EPrice ÷ TTM EPS | -34.32x | 2.21x | 50.32x | 37.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.16x | 58.29x | 31.41x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.35x |
| EV / EBITDAEnterprise value multiple | 0.09x | 3.29x | 42.68x | 20.47x |
| Price / SalesMarket cap ÷ Revenue | 0.15x | 0.23x | 2.82x | 4.07x |
| Price / BookPrice ÷ Book value/share | 3.13x | 0.44x | 12.25x | 7.14x |
| Price / FCFMarket cap ÷ FCF | 2.21x | 7.50x | 89.61x | 378.98x |
Profitability & Efficiency
BODI leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-11 for BODI. BODI carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), BODI scores 6/9 vs HIMS's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -11.4% | +20.4% | +23.7% | +23.3% |
| ROA (TTM)Return on assets | -1.9% | +11.3% | +6.0% | +11.5% |
| ROICReturn on invested capital | +46.7% | +7.3% | +10.7% | +14.7% |
| ROCEReturn on capital employed | +14.9% | +7.9% | +10.9% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.09x | 0.45x | 2.07x | 0.37x |
| Net DebtTotal debt minus cash | -$36M | $126M | $892M | $66.2B |
| Cash & Equiv.Liquid assets | $39M | $239M | $229M | $86.8B |
| Total DebtShort + long-term debt | $3M | $364M | $1.1B | $153.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.61x | 15.14x | — | 39.96x |
Total Returns (Dividends Reinvested)
AMZN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $279 for BODI. Over the past 12 months, BODI leads with a +186.6% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors AMZN at 36.8% vs NUS's -38.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +49.4% | -26.9% | -23.2% | +19.7% |
| 1-Year ReturnPast 12 months | +186.6% | +26.3% | -51.0% | +43.7% |
| 3-Year ReturnCumulative with dividends | -41.4% | -77.1% | +116.6% | +156.2% |
| 5-Year ReturnCumulative with dividends | -97.2% | -80.0% | +137.6% | +64.8% |
| 10-Year ReturnCumulative with dividends | -97.3% | -48.8% | +161.9% | +697.8% |
| CAGR (3Y)Annualised 3-year return | -16.3% | -38.9% | +29.4% | +36.8% |
Risk & Volatility
Evenly matched — BODI and AMZN each lead in 1 of 2 comparable metrics.
Risk & Volatility
BODI is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMZN currently trades 97.3% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.47x | 2.48x | 1.50x |
| 52-Week HighHighest price in past year | $16.79 | $14.62 | $70.43 | $278.56 |
| 52-Week LowLowest price in past year | $3.38 | $5.65 | $13.74 | $185.01 |
| % of 52W HighCurrent price vs 52-week peak | +83.8% | +48.0% | +36.4% | +97.3% |
| RSI (14)Momentum oscillator 0–100 | 54.0 | 46.4 | 54.5 | 81.1 |
| Avg Volume (50D)Average daily shares traded | 72K | 458K | 34.9M | 45.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NUS as "Hold", HIMS as "Hold", AMZN as "Buy". Consensus price targets imply 56.7% upside for NUS (target: $11) vs 2.1% for HIMS (target: $26). NUS is the only dividend payer here at 3.35% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $11.00 | $26.20 | $306.77 |
| # AnalystsCovering analysts | — | 11 | 19 | 94 |
| Dividend YieldAnnual dividend ÷ price | — | +3.4% | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | $0.24 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.8% | +1.4% | 0.0% |
BODI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). AMZN leads in 1 (Total Returns). 2 tied.
BODI vs NUS vs HIMS vs AMZN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BODI or NUS or HIMS or AMZN a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -39. 9% for The Beachbody Company, Inc. (BODI). Nu Skin Enterprises, Inc. (NUS) offers the better valuation at 2. 2x trailing P/E (7. 2x forward), making it the more compelling value choice. Analysts rate Amazon. com, Inc. (AMZN) a "Buy" — based on 94 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BODI or NUS or HIMS or AMZN?
On trailing P/E, Nu Skin Enterprises, Inc.
(NUS) is the cheapest at 2. 2x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Nu Skin Enterprises, Inc. is actually cheaper at 7. 2x.
03Which is the better long-term investment — BODI or NUS or HIMS or AMZN?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -97. 2% for The Beachbody Company, Inc. (BODI). Over 10 years, the gap is even starker: AMZN returned +702. 2% versus BODI's -97. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BODI or NUS or HIMS or AMZN?
By beta (market sensitivity over 5 years), The Beachbody Company, Inc.
(BODI) is the lower-risk stock at 1. 22β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 103% more volatile than BODI relative to the S&P 500. On balance sheet safety, The Beachbody Company, Inc. (BODI) carries a lower debt/equity ratio of 9% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BODI or NUS or HIMS or AMZN?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -39. 9% for The Beachbody Company, Inc. (BODI). On earnings-per-share growth, the picture is similar: Nu Skin Enterprises, Inc. grew EPS 207. 8% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BODI or NUS or HIMS or AMZN?
Amazon.
com, Inc. (AMZN) is the more profitable company, earning 10. 8% net margin versus -1. 1% for The Beachbody Company, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMZN leads at 11. 2% versus 3. 2% for BODI. At the gross margin level — before operating expenses — BODI leads at 73. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BODI or NUS or HIMS or AMZN more undervalued right now?
On forward earnings alone, Nu Skin Enterprises, Inc.
(NUS) trades at 7. 2x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 51. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUS: 56. 7% to $11. 00.
08Which pays a better dividend — BODI or NUS or HIMS or AMZN?
In this comparison, NUS (3.
4% yield) pays a dividend. BODI, HIMS, AMZN do not pay a meaningful dividend and should not be held primarily for income.
09Is BODI or NUS or HIMS or AMZN better for a retirement portfolio?
For long-horizon retirement investors, Nu Skin Enterprises, Inc.
(NUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 4% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUS: -48. 4%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BODI and NUS and HIMS and AMZN?
These companies operate in different sectors (BODI (Communication Services) and NUS (Consumer Defensive) and HIMS (Healthcare) and AMZN (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BODI is a small-cap quality compounder stock; NUS is a small-cap deep-value stock; HIMS is a small-cap high-growth stock; AMZN is a mega-cap quality compounder stock. NUS pays a dividend while BODI, HIMS, AMZN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.